JBS Science

Executive Summary

JBS Science is a private diagnostics company leveraging its proprietary circulating cell-free DNA (cfDNA) technology in urine to develop non-invasive liquid biopsy tests for cancer screening and management. Founded in 2008 and headquartered in San Diego, the company aims to reduce global cancer mortality by enabling earlier detection and real-time monitoring through a simple, urine-based sample. Currently in Phase 2 development, JBS Science has not disclosed specific pipeline programs or funding details, but its focus on a non-invasive, low-cost platform positions it well in the rapidly growing liquid biopsy market. The company's technology differentiates itself by targeting both methylated and mutated cfDNA fragments from urine, potentially offering advantages in sensitivity and accessibility over blood-based approaches. While the company remains private and early-stage, its mission and technology align with the increasing demand for at-home or point-of-care cancer diagnostics.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2 clinical trial for a lead urine-based cancer assay40% success
• H2 2026Announcement of a strategic partnership or licensing deal with a diagnostic or pharma partner30% success
• Q1 2027Disclosure of preliminary Phase 2 data for bladder or prostate cancer detection25% success